Advertisement
PHAT vs URGN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a Buy and URGN is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PHAT’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).
- PHAT’s FA Score: 0 green, 5 red.
- URGN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PHAT’s TA Score shows that 5 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).
- PHAT’s TA Score: 5 bullish, 5 bearish.
- URGN’s TA Score: 4 bullish, 3 bearish.
Price Growth
PHAT (@Biotechnology) experienced а -4.09% price change this week, while URGN (@Biotechnology) price change was +5.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.
Reported Earning Dates
PHAT is expected to report earnings on Aug 06, 2026.
URGN is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Biotechnology (-3.21% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| PHAT | URGN | PHAT / URGN | |
| Capitalization | 870M | 1.92B | 45% |
| EBITDA | -90.89M | -120.28M | 76% |
| Gain YTD | -34.207 | 68.702 | -50% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 205M | 140M | 146% |
| Total Cash | 181M | 140M | 129% |
| Total Debt | 166M | 195M | 85% |
PHAT | URGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 47 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 42 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 44 | 35 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
URGN's Valuation (60) in the Biotechnology industry is in the same range as PHAT (68) in the null industry. This means that URGN’s stock grew similarly to PHAT’s over the last 12 months.
URGN's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for PHAT (100) in the null industry. This means that URGN’s stock grew somewhat faster than PHAT’s over the last 12 months.
URGN's SMR Rating (100) in the Biotechnology industry is in the same range as PHAT (100) in the null industry. This means that URGN’s stock grew similarly to PHAT’s over the last 12 months.
URGN's Price Growth Rating (35) in the Biotechnology industry is in the same range as PHAT (44) in the null industry. This means that URGN’s stock grew similarly to PHAT’s over the last 12 months.
URGN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PHAT (100) in the null industry. This means that URGN’s stock grew similarly to PHAT’s over the last 12 months.
| PHAT | URGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 82% |
| Advances ODDS (%) | 4 days ago 85% | 5 days ago 81% |
| Declines ODDS (%) | 19 days ago 87% | N/A |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PJAN | 49.65 | -0.18 | -0.36% |
| Innovator US Equity Power Buff ETF™ Jan | |||
| BFEB | 52.78 | -0.25 | -0.47% |
| Innovator U.S. Equity Buffer ETF™ - Feb | |||
| BSR | 30.17 | -0.21 | -0.70% |
| Beacon Selective Risk ETF | |||
| CVNY | 21.09 | -0.20 | -0.94% |
| YieldMax CVNA Option Income Strategy ETF | |||
| VUSG | 63.40 | -1.22 | -1.88% |
| Vanguard Wellington U.S. Gr Actv ETF | |||